WallStSmart

Cerus Corporation (CERS)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 11569% more annual revenue ($25.27B vs $216.56M). SYK leads profitability with a 13.2% profit margin vs -4.4%. SYK earns a higher WallStSmart Score of 59/100 (C).

CERS

Avoid

31

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -5.79

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CERS.

SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CERS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
24.1%8/10

Revenue surging 24.1% year-over-year

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

CERS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$559.03M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.443/10

Elevated debt levels

Return on EquityProfitability
-14.1%2/10

ROE of -14.1% — below average capital efficiency

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CERS

The strongest argument for CERS centers on Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : CERS

The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CERS profiles as a growth stock while SYK is a value play — different risk/reward profiles.

CERS carries more volatility with a beta of 1.77 — expect wider price swings.

CERS is growing revenue faster at 24.1% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cerus Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?